Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Merck & Co., Inc.NYSE: MRK

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $9.74B rose 175.2% year over year, ahead of the +65.7% change in trailing-twelve-month research & development. Sequentially, it fell 22.4% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Research & development amounted to 19.3% of revenue in FY2025, down 8.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +175.2% holds above the trailing-twelve-month pace of +65.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$9.74B-22.4% QoQ
Last fiscal yearDec 2025
$12.51B-30.2% YoY
LTMJun 2026
$28.35B+65.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+175.2%——
1 year-30.2%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
12.51B USD
Year-over-year change
-30.2%
4-year CAGR
+0.5%

Research & Development vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +65.7% is the highest of 10, against a peer median of +5.4%.
  • Research & development amounts to 42.7% of revenue for MRK, versus a peer median of 18.3%.
MRK Competitors
Research & Development for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$28.35B USD+65.7%-2.6%42.7%
JNJJohnson & JohnsonLTM Sep 2026$16.08B USD+2.4%+1.2%16.2%
AZNAstraZeneca PLCLTM Sep 2026$15.01B USD-0.3%+13.4%24.1%
LLYEli Lilly and CompanyLTM Jun 2026$14.6B USD+23.4%+22.9%18.3%
NVSNovartis AGLTM Jun 2026$11.28B USD+9.2%+5.4%20.3%
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
ABBVAbbVie Inc.LTM Sep 2026$9.96B USD-25.0%+11.8%15.1%
SNYSanofiLTM Jun 2026€8.11B EUR+5.4%+6.5%16.6%
AMGNAmgen Inc.LTM Jun 2026$7.64B USD+19.3%+16.3%20.0%
GILDGilead Sciences, Inc.LTM Jun 2026$6.07B USD+2.7%+5.2%19.9%
Peer median (excluding MRK) —+5.4%+6.5%18.3%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.7B59.28B60.12B64.17B64.93B
Cost of Revenue13.63B17.41B16.13B15.19B18.2B
Gross Profit35.08B41.87B43.99B48.98B46.73B
Gross Margin72.0%70.6%73.2%76.3%72.0%
Research & Development12.25B13.55B30.53B17.94B12.51B
Selling, General & Admin9.4B9.67B9.88B10.1B10.73B
Operating Expenses21.88B23.59B41.04B28.75B23.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
EBITDA17.9B21.32B6.91B25.71B28.26B
EBITDA Margin36.8%36.0%11.5%40.1%43.5%
Operating Income13.2B18.28B2.95B20.22B23.49B
Operating Margin27.1%30.8%4.9%31.5%36.2%
Interest Income36M157M365M415M343M
Interest Expense806M962M1.15B1.27B1.36B
Other Income / Expenses680M(1.84B)(1.07B)(285M)(2.42B)
Income Before Tax13.88B16.44B1.89B19.94B21.07B
Pre-Tax Margin28.5%27.7%3.1%31.1%32.4%
Income Tax Expense1.52B1.92B1.51B2.8B2.8B
Net Income13.05B14.52B365M17.12B18.25B
Net Margin26.8%24.5%0.6%26.7%28.1%
EPS (Basic)5.165.730.146.767.30
EPS (Diluted)5.145.710.146.747.28
Weighted Avg Shares2.53B2.53B2.55B2.53B2.5B
Weighted Avg Shares (Diluted)2.54B2.54B2.55B2.54B2.51B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.